Find the latest Corbus Pharmaceuticals Holdings CRBP analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability ...

Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Wednesday, March ...

Belghiti now expects that the biopharmaceutical company will post earnings of ($2.74) per share for the quarter, up from their previous forecast ... Shares of CRBP stock opened at $6.79 on Friday.

Fintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) with a Outperform recommendation. Analyst Price Forecast Suggests 690. ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has hit a 52-week low, trading at $5.91, down dramatically from its... Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has hit a ...

This was the stock's second consecutive day of losses.

Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the Earnings Calendar to see dates for upcoming earnings announcements.

This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. Corbus Pharmaceuticals (CRBP) has become technically an oversold ...